When Small Process Changes Become A Different MSC Product

During this final segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover a particularly strong manufacturing point. Even seemingly minor changes in cell culture, processing, or expansion can accumulate and create product drift, raising the question of when a modified process produces what is effectively a different cell therapy.